Identification of a novel gene fusion RNF213‑SLC26A11 in chronic myeloid leukemia by RNA-Seq

Zhou,Jian-Bo; Zhang,Ting; Wang,Ben-Fang; Gao,Hai-Zhen; Xu,Xin

doi:10.3892/mmr.2012.1183

Identification of a novel gene fusion RNF213‑SLC26A11 in chronic myeloid leukemia by RNA-Seq

Authors:
- Jian-Bo Zhou
- Ting Zhang
- Ben-Fang Wang
- Hai-Zhen Gao
- Xin Xu
View Affiliations

Affiliations: Department of Clinical Laboratories, Jiang Yin People's Hospital, Jiang Yin, Jiangsu 214400, P.R. China
Published online on: November 13, 2012 https://doi.org/10.3892/mmr.2012.1183
Pages: 591-597

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chronic myeloid leukemia (CML) was the first hematological malignancy to be associated with a specific genetic lesion. The Philadelphia translocation, producing a BCR‑ABL hybrid oncogene, is the most common mechanism of CML development. However, in the present study, b3a2, b2a2 and ela2 fusion junctions of the breakpoint cluster region (BCR)-V-abl Abelson murine leukemia viral oncogene homolog 1 (ABL) gene were not detected in patients diagnosed with CML three and four years previously. RNA-Seq technology, with an average coverage of ~30‑fold, was used to detect gene fusion events in a patient with a 6-year history of CML, identified to be in the chronic phase of the disease. Using deFuse and TopHat‑fusion programs with improved filtering methods, we identified two reliable gene fusions in a blood sample obtained from the CML patient, including extremely low expression levels of the classic BCR‑ABL1 gene fusion. In addition, a novel gene fusion involving the ring finger protein 213 (RNF213)-solute carrier family 26, member 11 (SLC26A11) was identified and validated by reverse transcription polymerase chain reaction. Further bioinformatic analysis revealed that specific domains of SLC26A11 were damaged, which may affect the function of sulfate transportation of the normal gene. The present study demonstrated that, in specific cases, alternative gene fusions, besides BCR‑ABL, may be associated with the development of CML.

View Figures

View References

1	Frazer R, Irvine AE and McMullin MF: Chronic myeloid leukaemia in the 21st century. Ulster Med J. 76:8–17. 2007.PubMed/NCBI
2	Faderl S, Talpaz M, Estrov Z and Kantarjian HM: Chronic myelogenous leukemia: biology and therapy. Ann Intern Med. 131:207–219. 1999. View Article : Google Scholar
3	Nowefl PC and Hungerford DA: A minute chromosome in human chronic granulocytic leukemia. Science. 142:14971960.
4	Rowley JD: Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 243:290–293. 1973. View Article : Google Scholar
5	Tefferi A, Bren GD, Wagner KV, Schaid DJ, Ash RC and Thibodeau SN: The location of the Philadelphia chromosomal breakpoint site and prognosis in chronic granulocytic leukemia. Leukemia. 4:839–842. 1990.PubMed/NCBI
6	Lugo TG, Pendergast AM, Muller AJ and Witte ON: Tyrosine kinase activity and transformation potency of BCR-ABL oncogene products. Science. 247:1079–1082. 1990. View Article : Google Scholar : PubMed/NCBI
7	Shtivelman E, Lifshitz B, Gale RP and Canaani E: Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature. 315:550–554. 1985. View Article : Google Scholar : PubMed/NCBI
8	Mitelman F, Johansson B and Mertens F: The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer. 7:233–245. 2007. View Article : Google Scholar : PubMed/NCBI
9	Ha KC, Lalonde E, Li L, et al: Identification of gene fusion transcripts by transcriptome sequencing in BRCA1-mutated breast cancers and cell lines. BMC Med Genomics. 4:752011. View Article : Google Scholar : PubMed/NCBI
10	Maher CA, Kumar-Sinha C, Cao X, et al: Transcriptome sequencing to detect gene fusions in cancer. Nature. 458:97–101. 2009. View Article : Google Scholar : PubMed/NCBI
11	Tang F, Barbacioru C, Wang Y, et al: mRNA-Seq whole-transcriptome analysis of a single cell. Nat Methods. 6:377–382. 2009. View Article : Google Scholar : PubMed/NCBI
12	Mortazavi A, Williams BA, McCue K, Schaeffer L and Wold B: Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods. 5:621–628. 2008. View Article : Google Scholar : PubMed/NCBI
13	Wang Z, Gerstein M and Snyder M: RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet. 10:57–63. 2009. View Article : Google Scholar : PubMed/NCBI
14	Trapnell C, Pachter L and Salzberg SL: TopHat: discovering splice junctions with RNA-Seq. Bioinformatics. 25:1105–1111. 2009. View Article : Google Scholar : PubMed/NCBI
15	Roberts A, Trapnell C, Donaghey J, Rinn JL and Pachter L: Improving RNA-Seq expression estimates by correcting for fragment bias. Genome Biol. 12:R222011. View Article : Google Scholar : PubMed/NCBI
16	Jiang H and Wong WH: Statistical inferences for isoform expression in RNA-Seq. Bioinformatics. 25:1026–1032. 2009. View Article : Google Scholar : PubMed/NCBI
17	Hubbard TJ, Aken BL, Ayling S, et al: Ensembl 2009. Nucleic Acids Res. 37:D690–D697. 2009. View Article : Google Scholar : PubMed/NCBI
18	McPherson A, Hormozdiari F, Zayed A, et al: deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data. PLoS Comput Biol. 7:e10011382011. View Article : Google Scholar : PubMed/NCBI
19	Kim D and Salzberg SL: TopHat-Fusion: an algorithm for discovery of novel fusion transcripts. Genome Biol. 12:R722011. View Article : Google Scholar : PubMed/NCBI
20	Steidl C, Shah SP, Woolcock BW, et al: MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature. 471:377–381. 2011. View Article : Google Scholar : PubMed/NCBI
21	Nacu S, Yuan W, Kan Z, et al: Deep RNA sequencing analysis of readthrough gene fusions in human prostate adenocarcinoma and reference samples. BMC Med Genomics. 4:112011. View Article : Google Scholar : PubMed/NCBI
22	Melo JV, Gordon DE, Cross NC and Goldman JM: The ABL-BCR fusion gene is expressed in chronic myeloid leukemia. Blood. 81:158–165. 1993.PubMed/NCBI
23	Quintas-Cardama A and Cortes J: Molecular biology of BCR-ABL1-positive chronic myeloid leukemia. Blood. 113:1619–1630. 2009. View Article : Google Scholar : PubMed/NCBI
24	Deininger MW, Goldman JM and Melo JV: The molecular biology of chronic myeloid leukemia. Blood. 96:3343–3356. 2000.PubMed/NCBI
25	Verma D, Kantarjian HM, Jones D, et al: Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes and prognostic significance. Blood. 114:2232–2235. 2009. View Article : Google Scholar : PubMed/NCBI
26	Skotheim RI, Thomassen GO, Eken M, et al: A universal assay for detection of oncogenic fusion transcripts by oligo microarray analysis. Mol Cancer. 8:52009. View Article : Google Scholar : PubMed/NCBI
27	Chen W, Kalscheuer V, Tzschach A, et al: Mapping translocation breakpoints by next-generation sequencing. Genome Res. 18:1143–1149. 2008. View Article : Google Scholar : PubMed/NCBI
28	Campbell PJ, Stephens PJ, Pleasance ED, et al: Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nat Genet. 40:722–729. 2008. View Article : Google Scholar : PubMed/NCBI
29	Hermans A, Selleri L, Gow J and Grosveld GC: Absence of alternative splicing in BCR-ABL mRNA in chronic myeloid leukemia cell lines. Blood. 72:2066–2069. 1988.PubMed/NCBI
30	Vincourt JB, Jullien D, Amalric F and Girard JP: Molecular and functional characterization of SLC26A11, a sodium-independent sulfate transporter from high endothelial venules. FASEB J. 17:890–892. 2003.PubMed/NCBI
31	Pruitt KD, Tatusova T and Maglott DR: NCBI Reference Sequence (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteins. Nucleic Acids Res. 33:D501–D504. 2005. View Article : Google Scholar